scholarly journals Pancreatic solid serous cystadenoma: a rare entity that can lead to a futile surgery

2019 ◽  
Vol 2019 (12) ◽  
Author(s):  
Vincent Demesmaker ◽  
Faouzi Abou-Messaoud ◽  
Muriel Parent ◽  
Bernard Vanhoute ◽  
Fadi Maassarani ◽  
...  
Keyword(s):  
Palliative Chemotherapy ◽  
Serous Cystadenoma ◽  
Definitive Diagnosis ◽  
Emission Tomography ◽  
Pancreatic Tumors ◽  
Rare Entity ◽  
Resonance Imaging ◽  
Positron Emission ◽  
Final Histological Diagnosis

Abstract Although many types of pancreatic tumors exist, pancreatic solid serous cystadenoma stand as the most rare. Despite advances in medical imaging, definitive diagnosis remains complex. Here, we report a case of a 63-year-old man with a suspicious lesion of the pancreas discovered during a positron emission tomography–computed tomography. Despite an echo-endoscopy being performed, no biopsies were contributive. The magnetic resonance imaging did highlight another lesion in the liver. Due to the suspicion of a neuroendocrine tumor of the pancreas with liver metastases, a cephalic duodenopancreatectomy with partial hepatectomy was performed. During the procedure, another hepatic lesion was resected. The final histological diagnosis was a serous solid adenoma of the pancreas associated with a cholangiocarcinoma. During the follow-up, the patient presented a massive metastatic hepatic relapse even after the administration of a palliative chemotherapy.

Epithelioid Sarcoma of the Peripheral Nerve: Clinicopathologic Series of Three Cases and Literature Review

2020 ◽  
Author(s):  
Julio A Diaz-Perez ◽  
Smiljana Spasic ◽  
Jaylou M Velez-Torres ◽  
Edward F McCarthy ◽  
Andrew E Rosenberg
Keyword(s):  
Magnetic Resonance Imaging ◽  
Literature Review ◽  
Peripheral Nerve ◽  
Epithelioid Sarcoma ◽  
Emission Tomography ◽  
Wide Resection ◽  
Resonance Imaging ◽  
Positron Emission ◽  
Weighted Magnetic Resonance Imaging

Abstract Objectives Epithelioid sarcoma (ES) rarely arises in the nerve. To increase our understanding of this unusual tumor originating in the nerve, we describe the features of three cases and review the literature. Methods Clinical data, imaging, pathology, treatment, and follow-up are detailed. A systematic literature review was conducted. Results Two patients were male and one female; the median age was 24 years. The patients had neurologic symptoms, and the tumors arose in large nerves and ranged from 2.4 to 5.8 cm. The tumors were avid on positron emission tomography–computed tomography and showed increased signal intensity on T2-weighted magnetic resonance imaging. Centered in the nerve, the tumors grew with an infiltrative pattern and encased the nerve fascicles. All were treated with wide resection, and adjuvant treatment included combinations of chemotherapy and radiation. One recurred, and the limb was amputated. Metastases were documented to lymph nodes, lung, pleura, and skin. One patient died of disease after 54 months. Literature review including our cases showed that tumors stained with pancytokeratin (9/9), EMA (4/4), and CD34 (7/7); there was loss of INI1 in all six cases tested. Conclusions ES rarely arises in the peripheral nerve, and its infiltrative nature often requires morbid surgery. The differential includes a variety of benign and malignant epithelioid neoplasms.

scholarly journals Cerebral proliferative angiopathy: Clinical, angiographic features and literature review

2015 ◽  
Vol 22 (1) ◽  
pp. 101-107 ◽  
Author(s):  
Peng Liu ◽  
Xianli Lv ◽  
Ming Lv ◽  
Youxiang Li
Keyword(s):  
Clinical Symptoms ◽  
Emission Computed Tomography ◽  
Rare Entity ◽  
Resonance Imaging ◽  
Period Range ◽  
Positron Emission ◽  
Revascularization Surgery ◽  
Selection Of ◽  
Time Point

Purpose Here we present our experience with five cerebral proliferative angiopathy (CPA) patients to better delineate the clinical and angiographic features as well as the treatment selection of this disease. Methods Between October 2008 and October 2012, five consecutive patients diagnosed with CPA were admitted to our department in our hospital. All the five patients received magnetic resonance imaging, digital subtraction angiography, and positron emission computed tomography (PET) to definitively confirm this disease. We also collected 15 previously published instances of CPA to analyze the characteristics of this rare entity. Results As to the five patients, three were female and two were male, between the ages of 4 and 52 years with a mean age of 24.8 ± 20.6 years. The PET results showed that perfusion was decreased over the affected hemispheres in all five patients. As to the treatment, only one patient received encephalo-duro-arterio-synangiosis (EDAS) revascularization surgery. The other four patients were conservatively observed. During the follow-up period (range 3–6 years, mean 4 ± 1.9 years), the patient who underwent EDAS surgery manifested relief of clinical symptoms. In the conservative series, the symptoms in two patients aggravated and suffered permanent neurologic deficits. Conclusion CPA is a rare entity. Natural history has showed this disease is not stable and may progress at a certain time point. The EDAS procedure may be a treatment for CPA-related oligemia since there is currently little data and follow-up available.

scholarly journals Radiolabeled PET/MRI Nanoparticles for Tumor Imaging

2019 ◽  
Vol 9 (1) ◽  
pp. 89 ◽  
Author(s):  
Ernesto Forte ◽  
Dario Fiorenza ◽  
Enza Torino ◽  
Angela Costagliola di Polidoro ◽  
Carlo Cavaliere ◽  
...  
Keyword(s):  
Cancer Diagnosis ◽  
Multimodal Imaging ◽  
Tumor Imaging ◽  
Therapeutic Agents ◽  
Cellular Level ◽  
Emission Tomography ◽  
Resonance Imaging ◽  
Positron Emission ◽  
Magnetic Resonance Imaging Mri

The development of integrated positron emission tomography (PET)/magnetic resonance imaging (MRI) scanners opened a new scenario for cancer diagnosis, treatment, and follow-up. Multimodal imaging combines functional and morphological information from different modalities, which, singularly, cannot provide a comprehensive pathophysiological overview. Molecular imaging exploits multimodal imaging in order to obtain information at a biological and cellular level; in this way, it is possible to track biological pathways and discover many typical tumoral features. In this context, nanoparticle-based contrast agents (CAs) can improve probe biocompatibility and biodistribution, prolonging blood half-life to achieve specific target accumulation and non-toxicity. In addition, CAs can be simultaneously delivered with drugs or, in general, therapeutic agents gathering a dual diagnostic and therapeutic effect in order to perform cancer diagnosis and treatment simultaneous. The way for personalized medicine is not so far. Herein, we report principles, characteristics, applications, and concerns of nanoparticle (NP)-based PET/MRI CAs.

Simultaneous occurrence of hepatic alveolar and cystic echinococcosis

2019 ◽  
Vol 94 ◽  
Author(s):  
B. Ran ◽  
M. Wang ◽  
W. Jian ◽  
T. Jiang ◽  
R. Zhang ◽  
...  
Keyword(s):  
Cystic Echinococcosis ◽  
Alveolar Echinococcosis ◽  
Surgical Intervention ◽  
Clinical Manifestations ◽  
Emission Tomography ◽  
Simultaneous Occurrence ◽  
Resonance Imaging ◽  
Germinal Layer ◽  
Positron Emission

Abstract The co-occurrence of hepatic cystic echinococcosis (CE) and alveolar echinococcosis (AE) is extremely rare. Here, we present the clinical manifestations and treatment outcomes of three cases with co-occurring CE and AE in the liver. Computed tomography (CT), magnetic resonance imaging and 18FFluorodeoxyglucose Positron Emission Tomography-CT were used for preoperative diagnosis. Specimens were taken intraoperatively and sent for pathological studies to confirm the coexistence of CE and AE by laminated membrane, daughter cysts or germinal layer and infiltration structure. Albendazole was prescribed after operation for 12 months. All patients were completely recovered and showed no recurrence at last follow-up. Therefore, surgical intervention and postoperative application of albendazole are recommended for patients with concurrence of hepatic AE and CE.

Positron Emission Tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus Magnetic Resonance Imaging in the Diagnosis of Recurrent Gliomas

Neurosurgery ◽  
2005 ◽  
Vol 57 (3) ◽  
pp. 505-511 ◽  
Author(s):  
Walter Rachinger ◽  
Claudia Goetz ◽  
Gabriele Pöpperl ◽  
Franz Josef Gildehaus ◽  
Friedrich Wilhelm Kreth ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Positron Emission Tomography ◽  
Multimodal Treatment ◽  
Tumor Recurrence ◽  
Emission Tomography ◽  
Resonance Imaging ◽  
Fet Pet ◽  
Positron Emission ◽  
The Difference

ABSTRACT OBJECTIVE: New treatment modalities are available for patients with glioma, which may lead to unspecific changes in posttherapeutic magnetic resonance imaging (MRI) findings. Differentiation between tumor- and therapy-associated contrast enhancement on MRI scans after treatment may be difficult. The aim of this study was to analyze the diagnostic value of O-(2-[18F]fluoroethyl)-l-tyrosine (FET)-positron emission tomography (PET) and MRI in the detection of tumor recurrence in patients with glioma after radiotherapy, radiosurgery, or multimodal treatment. METHODS: The study included 36 patients with gliomas and neuroradiological diagnosis of tumor recurrence and 9 patients who had undergone radioimmunotherapy. Patients were consecutively treated between September 2001 and May 2003. A contemporary FET-PET investigation was performed in all patients. A tissue diagnosis was made for comparative analysis in all patients with progressive neuroradiological or clinical findings (32 of 45 patients). In patients with transient neuroradiological or clinical deterioration (13 of 45 patients), clinical follow-up was used to support or contradict the imaging-based diagnosis. RESULTS: Tumor recurrence was documented in 31 of 45 patients, and 14 of 45 patients were tumor free. FET-PET and MRI revealed a correct diagnosis in 44 and 36 patients, respectively. The difference was statistically significant (P < 0.01). Concordant findings after MRI and FET-PET were documented in 37 patients and discordant findings in 8 patients. The difference was statistically significant (P < 0.01). Specificity of FET-PET was 92.9%, and sensitivity was 100% (in patients suspected of having recurrent tumor as revealed by MRI). Sensitivity of MRI was 93.5%, and specificity was 50% (P < 0.05). CONCLUSION: For patients with gliomas undergoing multimodal treatment or various forms of irradiation, conventional follow-up with MRI is insufficient to distinguish between benign side effects of therapy and tumor recurrence. FET-PET is a powerful tool to improve the differential diagnosis in these patients.

Clinical Usefulness of Coregistered 11C-Methionine Positron Emission Tomography/3-T Magnetic Resonance Imaging at the Follow-Up of Acromegaly

2014 ◽  
Vol 82 (3-4) ◽  
pp. 468-473 ◽  
Author(s):  
Sandra Rodriguez-Barcelo ◽  
Antonio Gutierrez-Cardo ◽  
Miguel Dominguez-Paez ◽  
Juan Medina-Imbroda ◽  
Lorena Romero-Moreno ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Positron Emission Tomography ◽  
Magnetic Resonance ◽  
Clinical Usefulness ◽  
Emission Tomography ◽  
Resonance Imaging ◽  
Positron Emission
Sign in / Sign up

Export Citation Format

Share Document